Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00622843 · ClinicalTrials.gov registry record · Phase 3
Pneumococcal Conjugate Vaccination in HIV in Comparison to Polysaccharide Vaccine Boosting
A Phase 3 study of HIV Infections and Streptococcus Pneumoniae, sponsored by Henry M. Jackson Foundation for the Advancement of Military Medicine.
- Completed
- Registry status
- Phase 3
- Development phase
- 275
- Enrollment target
- 6
- Study locations
NCT00622843: Completed Phase 3 study of HIV Infections and Streptococcus Pneumoniae, sponsored by Henry M. Jackson Foundation for the Advancement of Military Medicine.
NCT00622843 is a Phase 3 study of HIV Infections and Streptococcus Pneumoniae that has completed, run by Henry M. Jackson Foundation for the Advancement of Military Medicine. The registered enrollment target is 275 participants, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (38% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00622843, a Phase 3 study of HIV Infections and Streptococcus Pneumoniae, has completed, sponsored by Henry M. Jackson Foundation for the Advancement of Military Medicine.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 275 participants
- Enrollment target
- 6
- Study locations
Study Summary
Purpose: To study the immune response of the newly licensed pneumococcal conjugate vaccine (PCV) in comparison to the pneumococcal polysaccharide vaccine (PPV) to determine if a significantly better immunologic response to boosting can be elicited in patients previously vaccinated with PPV.
Primary Outcome
The primary end point is greater than or equal to a 2-fold increase in the IgG level for at least 2 of the 4 serotypes on day 60, with levels greater than or equal to 1000 ng/mL.
Conditions Studied
Interventions
- BIOLOGICAL pneumococcal conjugate vaccine
- BIOLOGICAL pneumococcal polysaccharide vaccine
Study Locations (6)
California
- Naval Medical Center San Diego - San Diego
District of Columbia
- Walter Reed Army Medical Center - Washington D.C.
Hawaii
- Tripler Army Medical Center - Tripler AMC
Maryland
- National Naval Medical Center - Bethesda
Texas
- San Antonio Military Medical Center - Lackland Air Force Base
Virginia
- Naval Medical Center Portsmouth - Portsmouth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 275 participants |
| Start Date | 2002-12 |
| Est. Completion | 2013-07 |
| Phase | Phase 3 |
What the finished NCT00622843 record still lists
NCT00622843 is an interventional study that assigns participants to a tested intervention. The registered 275 participants enrollment target is mid-sized for trials with a published cap, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (38% lower).
The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which pneumococcal conjugate vaccine is the first listed.
NCT00622843 lists 6 locations in 6 states (California, District of Columbia, Hawaii).
Frequently Asked Questions
What is clinical trial NCT00622843 about?
NCT00622843 is a clinical study titled "Pneumococcal Conjugate Vaccination in HIV in Comparison to Polysaccharide Vaccine Boosting". Purpose: To study the immune response of the newly licensed pneumococcal conjugate vaccine (PCV) in comparison to the pneumococcal polysaccharide vaccine (PPV) to determine if a significantly better immunologic response to boosting can be elicited in patients previously vaccinated with PPV.
What is the current status of trial NCT00622843?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 275 participants. The study started on 2002-12. Estimated completion is 2013-07.
What conditions does trial NCT00622843 study?
This clinical trial studies the following conditions: HIV Infections, Streptococcus Pneumoniae.
What interventions are being tested in trial NCT00622843?
The interventions under investigation include: pneumococcal conjugate vaccine (BIOLOGICAL), pneumococcal polysaccharide vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00622843?
This trial is sponsored by Henry M. Jackson Foundation for the Advancement of Military Medicine, which has 60 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00622843 being conducted?
This trial has 6 study locations across California, District of Columbia, Hawaii, Maryland, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00622843's enrollment target sits among peer trials
275 131st of 542 higher than 411 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
RECRUITING · Phase 3
-
Testing a Real-time Electronic Antiretroviral Adherence Monitoring Intervention
RECRUITING · Phase 3
-
SmartSteps: A Context-Aware, PrEP Adherence Intervention for Individuals With Substance Use Disorder
RECRUITING · Phase 3
-
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF
ACTIVE NOT RECRUITING · Phase 3
-
The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269190 · 275 participants · NA
Wide-Field and High Resolution In Vivo Imaging in Visualizing Lesions in Patients With Oral Neoplasia Undergoing Surgery
- NCT01900132 · 275 participants · NA
Electrical Impedance Myography: Natural History Studies inNeuromuscular Disorders and Healthy Volunteers
- NCT04104776 · 275 participants · Phase 1
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- NCT04765150 · 275 participants
Integrating Quantitative MRI and Artificial Intelligence to Improve Prostate Cancer Classification
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia